Technology News and Research

RSS

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

4 Aug 2011

New urine test can aid in early detection of prostate cancer

A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.

4 Aug 2011

AMIA expresses concerns about HHS proposed rule

AMIA, the association for informatics professionals in biomedicine and health care, expressed its concerns to the U.S. Department of Health and Human Services (HHS) about a proposed rule that would modify the HIPAA Privacy Rules for accounting of disclosures.

4 Aug 2011

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NanoBio Corporation today announced a licensing agreement with the National Institutes of Health (NIH) that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

4 Aug 2011

ImmunoCellular receives new patent for ICT-69 to treat multiple myeloma, ovarian cancer

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer.

4 Aug 2011

Virginia Tech to develop, implement and evaluate food security for Southern Appalachians

While the popularity of locally and regionally grown food is on the rise among Americans, food accessibility remains a major concern for those with limited financial resources.

4 Aug 2011

Hopkins stem cell research to examine how gene variants cause blood clotting disorders

Johns Hopkins scientists have launched a pioneering research program to create, for the first time, human platelet cells from stem cells in order to study inherited blood clotting abnormalities ranging from clots that cause heart attacks and stroke to bleeding disorders.

4 Aug 2011

ImmunoGen revenues increase to $19.3 million for fiscal year 2011

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today reported financial results for the three-month period and fiscal year ended June 30, 2011.

4 Aug 2011

IDC Health Insights survey ranks Accenture as top life science IT services vendor

Accenture has been ranked as the number one life science information technology (IT) services vendor in a survey conducted by IDC Health Insights.

3 Aug 2011

Illumina and University of Oxford collaborate to sequence whole genomes

Illumina, Inc. today announced it will collaborate with the University of Oxford to sequence the whole genomes of 500 individuals afflicted with a range of life-threatening diseases that pose major challenges in diagnosis, treatment, and care. Illumina HiSeq™ 2000 systems will be used to generate sequence data for the 500 genomes.

From Illumina, Inc. 3 Aug 2011

Bruker second quarter revenue increases 33% y-o-y to $401.2 million

Bruker Corporation today reported financial results for the three and six months ended June 30, 2011.

3 Aug 2011

SIS receives U.S. patent for 3D SNAPSHOT

Spatial Integrated Systems, Inc., a leader in the development and integration of solutions incorporating next generation digital 3D data capture and processing technologies, announced today that it has been awarded U.S. patent 7,986,321 for a system and method for generating structured light for three-dimensional image rendering.

3 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

Aerogen receives Ruban d'Honneur award for global growth strategy

Irish company Aerogen, a medical device and drug delivery company has been awarded the internationally prestigious Ruban d'Honneur award in the European Business Awards.

3 Aug 2011

$Strengths and limitations of FRAX in assessing fracture risk$

Strengths and limitations of FRAX in assessing fracture risk

FRAX- is a computer-based algorithm developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases to help predict the 10-year risk of fragility fracture. Now with 34 specific country models, FRAX is being used increasingly by physicians around the world to help assess their patients' fracture risk in the course of a clinical assessment.

3 Aug 2011

BioClinica second quarter service revenues increase 8.7% to $16.9 million

BioClinica Inc., a global provider of clinical trial management solutions, today announced its financial results for the second quarter and six months ended June 30, 2011.

From Clario 3 Aug 2011

SXC enters definitive agreement to acquire PTRx

SXC Health Solutions Corp. announced today that it has entered into a definitive agreement to acquire PTRx, Inc., a full-service PBM, and SaveDirectRx, Inc., its exclusive mail-order pharmacy provider, both based in San Antonio.

3 Aug 2011

TeleTracking announces new hospital contracts for TransferCenter referral automation software

TeleTracking Technologies continued to expand its lead in the hospital capacity management market during the second quarter of 2011, spurred by 14 new hospital contracts for its category-leading TransferCenter™ referral automation software, which has become the fastest selling application in its product portfolio.

3 Aug 2011

New approach to overcome complexities of developing more effective drugs for treating diseases

Pharmaceutical scientists typically face a meager five percent success rate for anti-cancer drugs in clinical trials. To help improve this success rate, Japanese scientists, led by Dr. Tetsuya Terasaki, one of the top pharmaceutical scientists focused on drug transporters, have developed a new approach designed to overcome complexities of developing new, more effective drugs to treat diseases, including cancer.

3 Aug 2011